Genexine Inc
KOSDAQ:095700
Genexine Inc
Research & Development
Genexine Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genexine Inc
KOSDAQ:095700
|
Research & Development
-₩19.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
-45%
|
|
|
Celltrion Inc
KRX:068270
|
Research & Development
-₩218.9B
|
CAGR 3-Years
-91%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Research & Development
-₩71.4B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Research & Development
-₩17.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Research & Development
-₩28.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-31%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Research & Development
-₩95.6B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
Genexine Inc
Glance View
Genexine, Inc. engages in research and development of therapeutic vaccines hybrid Fc fusion proteins (hyFc) and DNA (deoxyribonucleic acid) therapeutic vaccines. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2009-09-15. The firm operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. The company also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
See Also
What is Genexine Inc's Research & Development?
Research & Development
-19.1B
KRW
Based on the financial report for Dec 31, 2024, Genexine Inc's Research & Development amounts to -19.1B KRW.
What is Genexine Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-45%
Over the last year, the Research & Development growth was 19%. The average annual Research & Development growth rates for Genexine Inc have been 16% over the past three years , 14% over the past five years , and -45% over the past ten years .
